Evaluation of the technical & commercial viability of developing an accelerated MERS vaccine

总部位于英国的英国生物技术初创公司Anglo Biumma Ltd将评估中东呼吸综合征（MERS）疫苗的商业和技术潜力。将对新型MERS疫苗对MERS的商业可行性进行评价。MERS是一种被世界卫生组织（WHO）主任描述为“对整个世界的威胁”的疾病。英美资源集团与阅读大学合作，将评估该大学杆状病毒平台产生新型疫苗候选抗原的潜力。

Anglo Biopharma Ltd, a UK based british biotech startup, will assess both the commercial and technical potential of a Middle Eastern Respiratory Syndrome (MERS) vaccine. An evaluation of the commercial viability of a novel MERS vaccine towards MERS will be performed. MERS is a disease described by the director of the World Health Organisation (WHO) as a "a threat to the entire world". Anglo Biopharma in colllaboration with the University of Reading will assess the potential of University's baculovirus platform's potential to generate novel vaccine antigen candidates.